Skip to main content

Table 4 Overall drop-out rate and main reasons for treatment discontinuation in the NEONet database

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

Patient population (n = 221)

Drop-out patients (70, 32 %)

Patients under treatment (151, 38 %)

p-value

Males, n (%)

25 (35.71)

68 (45.03)

0.0959

Females, n (%)

45 (64.29)

83 (54.97)

Age-years, mean (SD)

46.79 (14.82)

47.44 (13.11)

0.4904

Treatment duration-months, mean (SD)

27.69 (20.94)

27.54 (22.96)

0.4992

Reason for drop-out, n (%)

Lack of efficacy

18 (26)

  

Patient’s decision discontinuation

34 (49)

  

Efficacy

4 (6)

  

Adverse events (local or systemic reactions)

5 (7)

  

Onset of contraindications

6 (8)

  

Patient moved to another referral center

3 (4)

  
  1. NEONet North East Omalizumab Network, SD standard deviation